Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Bousbib AriOwnership Type:Direct OwnershipSecurities:Stock Appreciation RightNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-42,847Price:$65.16
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Bousbib AriOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:-11,169Price:$249.97
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Bousbib AriOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-15,417Price:$251.03
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Bousbib AriOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-16,261Price:$250.05
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Bousbib AriOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:42,847Price:$65.16
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Staub W RichardOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,068Price:$249.08
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Staub W RichardOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,062Price:$248.33
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Staub W RichardOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,970Price:$247.33
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Knightly Kevin COwnership Type:Direct OwnershipSecurities:Stock Appreciation RightNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-7,131Price:$95.23
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Knightly Kevin COwnership Type:Direct OwnershipSecurities:Stock Appreciation RightNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-6,075Price:$78.21
Filings by filing date
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Bousbib AriOwnership Type:Direct OwnershipSecurities:Stock Appreciation RightNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-42,847Price:$65.16
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Bousbib AriOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:-11,169Price:$249.97
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Bousbib AriOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-15,417Price:$251.03
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Bousbib AriOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-16,261Price:$250.05
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Bousbib AriOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:42,847Price:$65.16
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Staub W RichardOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,068Price:$249.08
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Staub W RichardOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,062Price:$248.33
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Staub W RichardOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,970Price:$247.33
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Knightly Kevin COwnership Type:Direct OwnershipSecurities:Stock Appreciation RightNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-7,131Price:$95.23
-
Feb 28, 2024 (filed on Mar 01, 2024)Insider Name:Knightly Kevin COwnership Type:Direct OwnershipSecurities:Stock Appreciation RightNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-6,075Price:$78.21
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2400 ELLIS ROAD DURHAM NC 27703 |
Tel: | 1-973-3163828 |
Website: | https://ir.iqvia.com |
IR: | See website |
Key People | ||
Ari Bousbib Chairman of the Board, Chief Executive Officer | Ronald E. Bruehlman Chief Financial Officer, Executive Vice President | Kevin C. Knightly President - Corporate Strategy and Enterprise Networks |
Walter Richard Staub President - Research and Development Solutions | Eric M. Sherbet Executive Vice President, General Counsel, Secretary |
Business Overview |
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The Company's Connected Intelligence delivers insights enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission critical information, technology solutions and real-world insights and services to life science clients. Research & Development Solutions primarily serves biopharmaceutical clients, provides outsourced clinical research and clinical trial services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market. |
Financial Overview |
For the fiscal year ended 31 December 2023, Iqvia Holdings Inc revenues increased 4% to $14.98B. Net income increased 24% to $1.36B. Revenues reflect Research & Development Solutions segment increase of 6% to $8.4B, Technology & Analytics Solutions segment increase of 2% to $5.86B. Net income benefited from Research & Development Solutions segment income increase of 13% to $1.92B. |
Employees: | 87,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $55,889M as of Dec 31, 2023 |
Annual revenue (TTM): | $14,984M as of Dec 31, 2023 |
EBITDA (TTM): | $3,186M as of Dec 31, 2023 |
Net annual income (TTM): | $1,358M as of Dec 31, 2023 |
Free cash flow (TTM): | $1,500M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $12,177M as of Dec 31, 2023 |
Shares outstanding: | 181,500,000 as of Dec 31, 2023 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |